DC Prime B.V.
|
DC Prime B.V. Employees in Amsterdam: 9 |
Company Profile
DCPrime BV is a spin-off company of the VU university medical center (VUmc) in Amsterdam, and focused on creating new therapeutic vaccines for the treatment of cancer and autoimmunity. The company develops products based on unique technologies developed at the VUmc. These include a panel of sustainable dendritic cell (DC) lines, and novel DC targeting technologies. DCPrime BV is gearing up to provide clinical proof-of-concept on DC lines for one indication before the end of 2009.Science and Technologies or Services
In one arm of its technology base, DCPrime develops sustainable DC lines that can be clinically applied as off-the-shelf DC vaccines. These can be loaded with the desired tumor antigens, but also with viral antigens or antigens for which tolerance is desirable. Also other genes of interest can be introduced into these DC lines without harming their antigen presentation potential, to introduce desirable modulations.
The first DC line, DCOne, is currently being prepared for entering clinical testing, and with several external partners. Scale-up procedures are being developed, and QA/QC compliant dossiers are being built on product specifications, production parameters, harvesting and storage conditions, quality assays, and reproducibility of all processes.
In the second arm of its technology base, DCPrime is performing pre-clinical validation of innovative DC targeting tools that can be directly applied to skin. The technological basis for these products will be prepared for strategic collaborations with co-development partners.
Alliances
DCPrime BV works together with the VU medical center, and with many life sciences companies and CRO’s in Europe.
Keywords
- Cancer
- Immunotherapy
- Autoimmunity
- Dendritic cells
